XML 63 R50.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Segment Disclosures (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Segment Reporting [Abstract] |
Summary Financial Information of Reportable Segment | The following tables summarize information for the reportable segments (in thousands): For the year ended December 31, 2021:
|  | Life Science |  | Medical Office |  | CCRC |  | Other Non-reportable |  | Corporate Non-segment |  | Total
Total revenues |  | $ | 715,844 |  |  | $ | 671,242 |  |  | $ | 471,325 |  |  | $ | 37,773 |  |  | $ | — |  |  | $ | 1,896,184 |
Government grant income(1) |  | — |  |  | — |  |  | 1,412 |  |  | — |  |  | — |  |  | 1,412 |
Less: Interest income |  | — |  |  | — |  |  | — |  |  | (37,773) |  |  | — |  |  | (37,773) |
Healthpeak's share of unconsolidated joint venture total revenues |  | 5,757 |  |  | 2,882 |  |  | 6,903 |  |  | 67,835 |  |  | — |  |  | 83,377 |
Healthpeak's share of unconsolidated joint venture government grant income |  | — |  |  | — |  |  | 200 |  |  | 1,549 |  |  | — |  |  | 1,749 |
Noncontrolling interests' share of consolidated joint venture total revenues |  | (292) |  |  | (35,363) |  |  | — |  |  | — |  |  | — |  |  | (35,655) |
Operating expenses |  | (169,044) |  |  | (223,383) |  |  | (380,865) |  |  | 13 |  |  | — |  |  | (773,279) |
Healthpeak's share of unconsolidated joint venture operating expenses |  | (1,836) |  |  | (1,174) |  |  | (6,639) |  |  | (51,866) |  |  | — |  |  | (61,515) |
Noncontrolling interests' share of consolidated joint venture operating expenses |  | 87 |  |  | 10,071 |  |  | — |  |  | — |  |  | — |  |  | 10,158 |
Adjustments to NOI(2) |  | (46,589) |  |  | (11,118) |  |  | 3,241 |  |  | (47) |  |  | — |  |  | (54,513) |
Adjusted NOI |  | 503,927 |  |  | 413,157 |  |  | 95,577 |  |  | 17,484 |  |  | — |  |  | 1,030,145 |
Plus: Adjustments to NOI(2) |  | 46,589 |  |  | 11,118 |  |  | (3,241) |  |  | 47 |  |  | — |  |  | 54,513 |
Interest income |  | — |  |  | — |  |  | — |  |  | 37,773 |  |  | — |  |  | 37,773 |
Interest expense |  | (232) |  |  | (2,837) |  |  | (7,701) |  |  | — |  |  | (147,210) |  |  | (157,980) |
Depreciation and amortization |  | (303,196) |  |  | (255,746) |  |  | (125,344) |  |  | — |  |  | — |  |  | (684,286) |
General and administrative |  | — |  |  | — |  |  | — |  |  | — |  |  | (98,303) |  |  | (98,303) |
Transaction costs |  | (24) |  |  | (323) |  |  | (1,445) |  |  | (49) |  |  | — |  |  | (1,841) |
Impairments and loan loss reserves, net |  | — |  |  | (21,577) |  |  | — |  |  | (1,583) |  |  | — |  |  | (23,160) |
Gain (loss) on sales of real estate, net |  | — |  |  | 190,590 |  |  | — |  |  | — |  |  | — |  |  | 190,590 |
Gain (loss) on debt extinguishments |  | — |  |  | — |  |  | — |  |  | — |  |  | (225,824) |  |  | (225,824) |
Other income (expense), net |  | 55 |  |  | (2,725) |  |  | 2,141 |  |  | 486 |  |  | 6,309 |  |  | 6,266 |
Less: Government grant income |  | — |  |  | — |  |  | (1,412) |  |  | — |  |  | — |  |  | (1,412) |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | (3,921) |  |  | (1,708) |  |  | (464) |  |  | (17,518) |  |  | — |  |  | (23,611) |
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | 205 |  |  | 25,292 |  |  | — |  |  | — |  |  | — |  |  | 25,497 |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |  | 243,403 |  |  | 355,241 |  |  | (41,889) |  |  | 36,640 |  |  | (465,028) |  |  | 128,367 |
Income tax benefit (expense) |  | — |  |  | — |  |  | — |  |  | — |  |  | 3,261 |  |  | 3,261 |
Equity income (loss) from unconsolidated joint ventures |  | 1,118 |  |  | 794 |  |  | 1,484 |  |  | 2,704 |  |  | — |  |  | 6,100 |
Income (loss) from continuing operations |  | 244,521 |  |  | 356,035 |  |  | (40,405) |  |  | 39,344 |  |  | (461,767) |  |  | 137,728 |
Income (loss) from discontinued operations |  | — |  |  | — |  |  | — |  |  | — |  |  | 388,202 |  |  | 388,202 |
Net income (loss) |  | $ | 244,521 |  |  | $ | 356,035 |  |  | $ | (40,405) |  |  | $ | 39,344 |  |  | $ | (73,565) |  |  | $ | 525,930 |
_______________________________________ (1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2). (2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures. For the year ended December 31, 2020:
|  | Life Science |  | Medical Office |  | CCRC |  | Other Non-reportable |  | Corporate Non-segment |  | Total
Total revenues |  | $ | 569,296 |  |  | $ | 622,398 |  |  | $ | 436,494 |  |  | $ | 16,687 |  |  | $ | — |  |  | $ | 1,644,875 |
Government grant income(1) |  | — |  |  | — |  |  | 16,198 |  |  | — |  |  | — |  |  | 16,198 |
Less: Interest income |  | — |  |  | — |  |  | — |  |  | (16,553) |  |  | — |  |  | (16,553) |
Healthpeak's share of unconsolidated joint venture total revenues |  | 448 |  | 2,772 |  | 35,392 |  | 74,023 |  | — |  | 112,635 |
Healthpeak's share of unconsolidated joint venture government grant income |  | — |  | — |  | 920 |  | 359 |  | — |  | 1,279 |
Noncontrolling interests' share of consolidated joint venture total revenues |  | (239) |  | (34,597) |  | — |  | — |  | — |  | (34,836) |
Operating expenses |  | (138,005) |  |  | (204,008) |  |  | (440,528) |  |  | — |  |  | — |  |  | (782,541) |
Healthpeak's share of unconsolidated joint venture operating expenses |  | (137) |  |  | (1,129) |  |  | (32,125) |  |  | (53,779) |  |  | — |  |  | (87,170) |
Noncontrolling interests' share of consolidated joint venture operating expenses |  | 72 |  |  | 10,282 |  |  | — |  |  | — |  |  | — |  |  | 10,354 |
Adjustments to NOI(2) |  | (20,133) |  |  | (5,544) |  |  | 97,072 |  |  | 433 |  |  | — |  |  | 71,828 |
Adjusted NOI |  | 411,302 |  |  | 390,174 |  |  | 113,423 |  |  | 21,170 |  |  | — |  |  | 936,069 |
Plus: Adjustments to NOI(2) |  | 20,133 |  |  | 5,544 |  |  | (97,072) |  |  | (433) |  |  | — |  |  | (71,828) |
Interest income |  | — |  |  | — |  |  | — |  |  | 16,553 |  |  | — |  |  | 16,553 |
Interest expense |  | (234) |  |  | (400) |  |  | (7,227) |  |  | — |  |  | (210,475) |  |  | (218,336) |
Depreciation and amortization |  | (217,921) |  |  | (222,165) |  |  | (113,851) |  |  | (12) |  |  | — |  |  | (553,949) |
General and administrative |  | — |  |  | — |  |  | — |  |  | — |  |  | (93,237) |  |  | (93,237) |
Transaction costs |  | (236) |  |  | — |  |  | (17,994) |  |  | (112) |  |  | — |  |  | (18,342) |
Impairments and loan loss reserves, net |  | (14,671) |  |  | (10,208) |  |  | — |  |  | (18,030) |  |  | — |  |  | (42,909) |
Gain (loss) on sales of real estate, net |  | — |  |  | 90,390 |  |  | — |  |  | (40) |  |  | — |  |  | 90,350 |
Gain (loss) on debt extinguishments |  | — |  |  | — |  |  | — |  |  | — |  |  | (42,912) |  |  | (42,912) |
Other income (expense), net |  | — |  |  | — |  |  | 187,844 |  |  | 41,707 |  |  | 5,133 |  |  | 234,684 |
Less: Government grant income |  | — |  |  | — |  |  | (16,198) |  |  | — |  |  | — |  |  | (16,198) |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | (311) |  |  | (1,643) |  |  | (4,187) |  |  | (20,603) |  |  | — |  |  | (26,744) |
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | 167 |  |  | 24,315 |  |  | — |  |  | — |  |  | — |  |  | 24,482 |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |  | 198,229 |  |  | 276,007 |  |  | 44,738 |  |  | 40,200 |  |  | (341,491) |  |  | 217,683 |
Income tax benefit (expense)(3) |  | — |  | — |  | — |  | — |  | 9,423 |  |  | 9,423 |
Equity income (loss) from unconsolidated joint ventures |  | (40) |  |  | 798 |  |  | (1,547) |  |  | (65,810) |  |  | — |  |  | (66,599) |
Income (loss) from continuing operations |  | 198,189 |  |  | 276,805 |  |  | 43,191 |  |  | (25,610) |  |  | (332,068) |  |  | 160,507 |
Income (loss) from discontinued operations |  | — |  |  | — |  |  | — |  |  | — |  |  | 267,746 |  |  | 267,746 |
Net income (loss) |  | $ | 198,189 |  |  | $ | 276,805 |  |  | $ | 43,191 |  |  | $ | (25,610) |  |  | $ | (64,322) |  |  | $ | 428,253 |
_______________________________________ (1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2). (2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures. (3)Income tax benefit (expense) for the year ended December 31, 2020 includes: (i) a $51 million tax benefit recognized in conjunction with internal restructuring activities, which resulted in the transfer of assets subject to certain deferred tax liabilities from taxable REIT subsidiaries to the REIT in connection with the 2019 MTCA (see Note 3), (ii) a $33 million income tax expense related to the valuation allowance on deferred tax assets that are no longer expected to be realized (see Note 17), and (iii) a $3.7 million net tax benefit recognized due to changes under the CARES Act, which resulted in net operating losses being utilized at a higher income tax rate than previously available. For the year ended December 31, 2019:
|  | Life Science |  | Medical Office |  | CCRC |  | Other Non-reportable |  | Corporate Non-segment |  | Total
Total revenues |  | $ | 440,784 |  |  | $ | 621,171 |  |  | $ | 3,010 |  |  | $ | 175,374 |  |  | $ | — |  |  | $ | 1,240,339 |
Less: Interest income |  | — |  |  | — |  |  | — |  |  | (9,844) |  |  | — |  |  | (9,844) |
Healthpeak's share of unconsolidated joint venture total revenues |  | — |  |  | 2,810 |  |  | 211,377 |  |  | 23,834 |  |  | — |  |  | 238,021 |
Noncontrolling interests' share of consolidated joint venture total revenues |  | (187) |  |  | (33,998) |  |  | — |  |  | 2,355 |  |  | — |  |  | (31,830) |
Operating expenses |  | (107,472) |  |  | (201,620) |  |  | (2,215) |  |  | (93,937) |  |  | — |  |  | (405,244) |
Healthpeak's share of unconsolidated joint venture operating expenses |  | — |  |  | (1,107) |  |  | (170,473) |  |  | (1,996) |  |  | — |  |  | (173,576) |
Noncontrolling interests' share of consolidated joint venture operating expenses |  | 59 |  |  | 10,109 |  |  | — |  |  | (1,536) |  |  | — |  |  | 8,632 |
Adjustments to NOI(1) |  | (22,103) |  |  | (4,602) |  |  | 16,985 |  |  | (5,449) |  |  | — |  |  | (15,169) |
Adjusted NOI |  | 311,081 |  |  | 392,763 |  |  | 58,684 |  |  | 88,801 |  |  | — |  |  | 851,329 |
Plus: Adjustments to NOI(1) |  | 22,103 |  |  | 4,602 |  |  | (16,985) |  |  | 5,449 |  |  | — |  |  | 15,169 |
Interest income |  | — |  |  | — |  |  | — |  |  | 9,844 |  |  | — |  |  | 9,844 |
Interest expense |  | (277) |  |  | (434) |  |  | — |  |  | — |  |  | (216,901) |  |  | (217,612) |
Depreciation and amortization |  | (168,339) |  |  | (221,175) |  |  | — |  |  | (45,677) |  |  | — |  |  | (435,191) |
General and administrative |  | — |  |  | — |  |  | — |  |  | — |  |  | (92,966) |  |  | (92,966) |
Transaction costs |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,963) |  |  | (1,963) |
Impairments and loan loss reserves, net |  | — |  |  | (17,332) |  |  | — |  |  | (376) |  |  | — |  |  | (17,708) |
Gain (loss) on sales of real estate, net |  | 3,651 |  |  | 3,139 |  |  | — |  |  | (6,830) |  |  | — |  |  | (40) |
Gain (loss) on debt extinguishments |  | — |  |  | — |  |  | — |  |  | — |  |  | (58,364) |  |  | (58,364) |
Other income (expense), net |  | — |  |  | — |  |  | (5,665) |  |  | 161,886 |  |  | 8,848 |  |  | 165,069 |
Less: Healthpeak's share of unconsolidated joint venture NOI |  | — |  |  | (1,703) |  |  | (40,904) |  |  | (21,838) |  |  | — |  |  | (64,445) |
Plus: Noncontrolling interests' share of consolidated joint venture NOI |  | 128 |  | 23,889 |  | — |  | (819) |  | — |  |  | 23,198 |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |  | 168,347 |  |  | 183,749 |  |  | (4,870) |  |  | 190,440 |  |  | (361,346) |  |  | 176,320 |
Income tax benefit (expense) |  | — |  |  | — |  |  | — |  |  | — |  |  | 5,479 |  |  | 5,479 |
Equity income (loss) from unconsolidated joint ventures |  | — |  |  | 858 |  |  | (16,313) |  |  | 9,125 |  |  | — |  |  | (6,330) |
Income (loss) from continuing operations |  | 168,347 |  |  | 184,607 |  |  | (21,183) |  |  | 199,565 |  |  | (355,867) |  |  | 175,469 |
Income (loss) from discontinued operations |  | — |  |  | — |  |  | — |  |  | — |  |  | (115,408) |  |  | (115,408) |
Net income (loss) |  | $ | 168,347 |  |  | $ | 184,607 |  |  | $ | (21,183) |  |  | $ | 199,565 |  |  | $ | (471,275) |  |  | $ | 60,061 |
_______________________________________ (1)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.
Summary of Reconciliation of Company's Revenues to Total Revenues | The following table summarizes the Company’s revenues by segment (in thousands):
|  | Year Ended
|  | December 31,
Segments |  | 2021 |  | 2020 |  | 2019
Life science |  | $ | 715,844 |  |  | $ | 569,296 |  |  | $ | 440,784 |
Medical office |  | 671,242 |  |  | 622,398 |  |  | 621,171 |
CCRC |  | 471,325 |  |  | 436,494 |  |  | 3,010 |
Other non-reportable |  | 37,773 |  |  | 16,687 |  |  | 175,374 |
Total revenues |  | $ | 1,896,184 |  |  | $ | 1,644,875 |  |  | $ | 1,240,339 |
Summary of Reconciliation of Company's Assets to Total Assets | The following table summarizes the Company’s total assets by segment (in thousands):
|  | December 31,
Segment |  | 2021 |  | 2020
Life science |  | $ | 8,257,990 |  |  | $ | 7,205,949 |
Medical office |  | 6,152,512 |  |  | 5,197,777 |
CCRC |  | 2,233,377 |  |  | 2,179,294 |
Reportable segment assets |  | 16,643,879 |  |  | 14,583,020 |
Accumulated depreciation and amortization |  | (3,125,416) |  |  | (2,658,890) |
Net reportable segment assets |  | 13,518,463 |  |  | 11,924,130 |
Other non-reportable segment assets |  | 794,172 |  |  | 584,432 |
Assets held for sale and discontinued operations, net |  | 37,190 |  |  | 2,626,306 |
Other non-segment assets |  | 907,694 |  |  | 785,221 |
Total assets |  | $ | 15,257,519 |  |  | $ | 15,920,089 |

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration